Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Immune-Onc Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Immune-Onc Therapeutics

Immune-Onc Therapeutics

Public

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

HQ
Palo Alto, CA, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Immune-Onc Therapeutics, Inc., founded in California, is a clinical-stage biopharmaceutical company dedicated to developing therapeutic antibodies for cancer treatment. The company's core mission is to advance the field of cancer immunotherapy by creating innovative treatments that harness the body's immune system to fight cancer. Their product pipeline focuses on addressing unmet medical needs in immunology and inflammation, blood cancers, and solid tumors.

Notable affiliated individuals include experts in oncology and immunotherapy, contributing to the company's robust research and development efforts. Immune-Onc Therapeutics has attracted significant investment from leading venture capital firms, underscoring confidence in its potential. Key achievements include progressing multiple candidates through clinical trials, demonstrating promising efficacy and safety profiles. The company's impact lies in its potential to offer new hope to cancer patients through cutting-edge immunotherapeutic solutions.

Immune-Onc Therapeutics - Similar Companies

Immunitas Therapeutics logo

Immunitas Therapeutics

immunitastx.com

Iovance Biotherapeutics logo

Iovance Biotherapeutics

iovance.com

OncoResponse logo

OncoResponse

INmune Bio logo

INmune Bio

inmunebio.com

Immunome logo

Immunome

Pionyr Immunotherapeutics logo

Pionyr Immunotherapeutics

Oncofactor logo

Oncofactor

oncofactor.com

Checkpoint Therapeutics logo

Checkpoint Therapeutics

checkpointtx.com

Imvaq Therapeutics logo

Imvaq Therapeutics

ImmunoGenesis logo

ImmunoGenesis

immunogenesis.com

Cancervax logo

Cancervax

cancervax.com

OncoPep logo

OncoPep

oncopep.com

ImmunoMet Therapeutics logo

ImmunoMet Therapeutics

immunomet.com

Bolt Biotherapeutics logo

Bolt Biotherapeutics

boltbio.com

Nantkwest logo

Nantkwest

Immune-Onc Therapeutics - Quick Facts

Who are Immune-Onc Therapeutics' competitors?

Companies similar to Immune-Onc Therapeutics include Immunitas Therapeutics, Iovance Biotherapeutics, OncoResponse and INmune Bio.

When was Immune-Onc Therapeutics founded?

Immune-Onc Therapeutics was founded in 2016.

Where is Immune-Onc Therapeutics' headquarters located?

Immune-Onc Therapeutics' headquarters is located in Palo Alto, CA, US.

When was Immune-Onc Therapeutics' last funding round?

Immune-Onc Therapeutics' most recent funding round was for $25M (USD) in January 2023.

How much has Immune-Onc Therapeutics raised to-date?

As of Jan 5, 2023, Immune-Onc Therapeutics has raised a total of $140.1M (USD).

How many employees does Immune-Onc Therapeutics have?

Immune-Onc Therapeutics has 35 employees as of Feb 5, 2024.

Immune-Onc Therapeutics - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Cancer Treatment
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified